

## Special Issue

# Lipid and Cholesterol Metabolism in Health and Disease: A Focus on the Cross-Talk between Peripheral Tissues and Central Nervous System

### Message from the Guest Editor

Cholesterol plays a fundamental role in the human body, at the central nervous system (CNS) level, cholesterol contributes to maintaining physiological brain function. Cholesterol can be obtained through diet and through endogenous synthesis. The correct metabolism of lipids also contributes to ensure key physiological functions. On the other hand, the alteration of cholesterol and lipid homeostasis represents a major risk for metabolic and cardiovascular disorders, whereas at the CNS level, its impairment appears to be involved in several neurological diseases. Moreover, although cholesterol metabolism in peripheral tissues is independent from metabolism in the brain due to the blood–brain barrier, the crosstalk between central and peripheral lipid metabolism still remains an underestimated item in both physiological and pathological conditions. Consequently, the main purpose of this Special Issue is to shed new knowledge on the possible connections between peripheral and central metabolism of lipid and cholesterol metabolism to identify possible novel targets aimed to develop a therapeutic strategy to counteract detrimental effects of their dysregulation in chronic diseases.

### Guest Editor

Dr. Micaela Gliozzi

Institute of Research for Food Safety and Health (IRC-FSH), Department of Health Sciences, University “Magna Graecia” of Catanzaro, Catanzaro, Italy

### Deadline for manuscript submissions

closed (31 March 2023)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/92966](https://mdpi.com/si/92966)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).